The key players in the drug manufacturing Cipla and Glenmark got the final approval for Arformoterol Tartrate Inhalation Solution from the United States Food and Drug Administration (US FDA). The solution provides relief from chronic bronchitis and emphysema. The Arformoterol Tartrate Inhalation Solution 15 mcg/2 ml stands as a basic version of Sunovion Pharmaceuticals Inc’s Brovana for both companies.
Patients with chronic obstructive pulmonary disease (COPD) require long-term administration of Brovana, a long-acting beta-2 adrenergic agonist (beta-2 agonist). The drug administration indication is twice a day (morning and evening). The US sales are nearly USD 438 million for the 12 months ending April 2021, per the IQVIA (IMS Health) data. Cipla has informed immediate shipping availability of the drug.
Glenmark said that the North American manufacturing facility based in Monroe, North Carolina, would contain the drug manufacturing wing. Additionally, this is the first nebulizer approval for the company. Presently, Glenmark comprises 172 products with a US market distribution license and 44 abbreviated new drug applications awaiting approval with the USFDA.
Being a leader in the pharma industry, Cipla is racing ahead with robust technological improvements to offer therapies for Covid. It has a comprehensive portfolio of drugs and diagnostic kits for the novel disease. The company marked extraordinary revenue due to strong sales in the Q4 profit, up 73% at Rs 412 crore, total income at Rs 4,606 crore. The drugmaker plans to tap the foreign markets for comprehensive coronavirus vaccine services.
Glenmark announced the consolidated revenue was at INR. 1,09,439 million, recording an increase of 2.8% over the previous corresponding period. The company hit a 23-month high in shares in April of Rs 587.50, up 3 percent, on the BSE in intra-day trade. The company also announced Glenmark Life Sciences’ IPO consisting of a fresh issue of shares worth INR 1,160 crore and a sale offer of nearly 7.31 million shares by parent Glenmark Pharmaceuticals.
The Indian pharmaceutical market (IPM) growth rate zoomed swiftly in April and May with 51.5% and 47.8% year-on-year, respectively. According to analyst reports, the demand for the Covid drugs led the sales. Additionally, the market saw a high need for anti-infectives, respiratory, and vitamins, and minerals that increased 142%, 87%, and 60% year on year, respectively.